2021-10-142021-10-142006Kurt, E. vd. (2006). ''Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer''. Tumori, 92(6), 481-486.0300-8916https://doi.org/10.1177/030089160609200603https://journals.sagepub.com/doi/10.1177/030089160609200603http://hdl.handle.net/11452/22344Aims and background: To evaluate the efficacy and tolerability of a new treatment approach including induction chemotherapy (CT) and concurrent chemoradiotherapy (CRT) in unresectable, locally advanced pancreatic cancer (LAPC). Patients and methods: Twenty-four patients with LAPC were enrolled in the study. They first received induction CT consisting of 5-fluorouracil (5FU) (500 mg/m(2)) and gemcitabine (1000 mg/m(2)), which were given weekly for 3 weeks of every 4. Patients showing a response or disease stabilization after 2 cycles of induction CT received CRT consisting of external beam radiotherapy (50.4-54 Gy in fractions of 1.8 Gy/day) and gemcitabine (350 mg/m(2), weekly for 6 weeks). Patients without disease progression received 2 additional cycles of CT consisting of 5FU plus gemcitabine with the same doses and schedule as given in the induction CT. Results: After the end of the study, 2 (13%) and 5 (21%) patients showed complete and partial responses, respectively. Five patients (21%) had disease stabilization. The grade 3 and 4 toxicities associated with CT were neutropenia (21%) and thrombocytopenia (4%). The grade 3 and 4 toxicities occurring in patients who received CRT were neutropenia (24%), thrombocytopenia (24%), diarrhea (18%), and nausea (12%). The median progression-free survival for all patients was 6 months (95% Cl, 3.6-8.4), and the median overall survival was 11 months (95% Cl, 8.16-13.84). Conclusions: The CRT approach of this study is moderately active and has an acceptable toxicity profile. However, the incorporation of combination CT into CRT at the present schedule could not produce any additional benefit over CRT alone. Newer agents with more systemic activity are clearly warranted.eninfo:eu-repo/semantics/closedAccessOncologyPancreatic carcinomaInduction chemotherapyChemoradiotherapyResectionCombinationChemoradiationSurvivalRadiotherapyCarcinomaTrialRadiation-therapyCooperative-oncology-groupArticle0002435752000032-s2.0-3384659976148148692617260487Oncology130-Nm Albumin-Bound Paclitaxel; Gemcitabine; Pancreatic NeoplasmsGfluorouracilGemcitabineFluorouracilAdultAdvanced cancerAgedAnemiaArticleBolus injectionCancer combination chemotherapyCancer radiotherapyCancer survivalClinical articleClinical trialControlled clinical trialControlled studyDiarrheaDisease courseDrug dose reductionDuodenum ulcerExternal beam radiotherapyFemaleHumanMaleMucosa inflammationNauseaNeutropeniaPancreas cancerThrombocytopeniaTreatment responsePhase 2 clinical trial